|
WO1989006692A1
(en)
*
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
US6884418B1
(en)
|
1989-08-04 |
2005-04-26 |
Berlex Laboratories, Inc. |
Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
|
|
JPH06501705A
(ja)
*
|
1990-11-05 |
1994-02-24 |
ブリストル−マイアーズ スクイブ カンパニー |
抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療
|
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
|
US6417168B1
(en)
|
1998-03-04 |
2002-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
|
JP2002515511A
(ja)
|
1998-05-15 |
2002-05-28 |
イムクローン システムズ インコーポレイティド |
放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
|
|
US9134303B1
(en)
|
1998-08-25 |
2015-09-15 |
Alere Scarborough, Inc. |
ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
|
|
US20080096236A1
(en)
*
|
1998-08-25 |
2008-04-24 |
Binax, Inc. |
Method for Detecting the Presence of Target Bacteria or a Target Component Carbohydrate Antigen Thereof
|
|
US6824997B1
(en)
|
1998-09-18 |
2004-11-30 |
Binax, Inc. |
Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
|
|
HK1047236A1
(zh)
*
|
1999-05-14 |
2003-02-14 |
Imclone Llc |
用表皮生长因子受体拮抗剂治疗难治的人肿瘤
|
|
TWI269654B
(en)
|
1999-09-28 |
2007-01-01 |
Baxter Healthcare Sa |
N-substituted indole-3-glyoxylamide compounds having anti-tumor action
|
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
|
JP2004511430A
(ja)
*
|
2000-05-24 |
2004-04-15 |
イムクローン システムズ インコーポレイティド |
二重特異性免疫グロブリン様抗原結合蛋白および製造方法
|
|
EP1170011A1
(de)
*
|
2000-07-06 |
2002-01-09 |
Boehringer Ingelheim International GmbH |
Neue Verwendung von Inhibitoren der Rezeptoren des epidermalen Wachstumsfaktors
|
|
JP2004527456A
(ja)
*
|
2000-08-09 |
2004-09-09 |
イムクローン システムズ インコーポレイティド |
Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
|
|
ATE419239T1
(de)
*
|
2000-10-20 |
2009-01-15 |
Eisai R&D Man Co Ltd |
Verfahren zur herstellung von 4-phenoxy chinolin derivaten
|
|
US7906492B2
(en)
*
|
2001-01-16 |
2011-03-15 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
|
US7507724B2
(en)
|
2001-01-16 |
2009-03-24 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
|
EP1381384B1
(de)
|
2001-04-24 |
2011-05-25 |
Merck Patent GmbH |
KOMBINATIONSTHERAPIE MIT ANTIANGIOGENEN MITTELN UND TNFalpha
|
|
DE60234094D1
(de)
|
2001-05-11 |
2009-12-03 |
Ludwig Inst For Cancer Res Ltd |
Spezifische bindungsproteine und ihre verwendung
|
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
|
JP4298498B2
(ja)
*
|
2001-06-13 |
2009-07-22 |
ゲンマブ エー／エス |
上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体
|
|
WO2003002144A1
(en)
*
|
2001-06-26 |
2003-01-09 |
Imclone Systems Incorporated |
Bispecific antibodies that bind to vegf receptors
|
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
|
CA2447851C
(en)
*
|
2001-06-28 |
2012-08-28 |
Domantis Limited |
Dual-specific ligand and its use
|
|
DE10133394A1
(de)
*
|
2001-07-13 |
2003-01-30 |
Merck Patent Gmbh |
Flüssige Formulierung enthaltend Cetuximab
|
|
ATE475431T1
(de)
|
2002-03-04 |
2010-08-15 |
Imclone Llc |
Kdr-spezifische humane antikörper und deren anwendung
|
|
JP4542783B2
(ja)
*
|
2002-03-05 |
2010-09-15 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
スルホンアミド含有複素環化合物及び血管新生抑制剤とを組み合わせてなる抗腫瘍剤
|
|
NZ571508A
(en)
|
2002-05-24 |
2010-05-28 |
Schering Corp |
Neutralizing human anti-IGFR antibody
|
|
US9321832B2
(en)
*
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
|
EP1517921B1
(de)
*
|
2002-06-28 |
2006-06-07 |
Domantis Limited |
Dual-specifische liganden mit erhöhter halbwertszeit
|
|
CN1703243B
(zh)
|
2002-10-10 |
2011-05-04 |
默克专利有限公司 |
针对erb-b1受体的药物组合物
|
|
US20040147428A1
(en)
*
|
2002-11-15 |
2004-07-29 |
Pluenneke John D. |
Methods of treatment using an inhibitor of epidermal growth factor receptor
|
|
US8505468B2
(en)
*
|
2002-11-19 |
2013-08-13 |
Sharp Kabushiki Kaisha |
Substrate accommodating tray
|
|
EP1578801A2
(de)
*
|
2002-12-27 |
2005-09-28 |
Domantis Limited |
Dual-spezifischer einzeldomäne-antikörper welcher spezifisch ist für einen liganden und dessen rezeptor
|
|
JPWO2004080462A1
(ja)
|
2003-03-10 |
2006-06-08 |
エーザイ株式会社 |
ｃ−Ｋｉｔキナーゼ阻害剤
|
|
EP1622941A2
(de)
*
|
2003-03-20 |
2006-02-08 |
ImClone Systems Incorporated |
Methode zur produktion von anti-egfr antikörpern
|
|
US7425328B2
(en)
*
|
2003-04-22 |
2008-09-16 |
Purdue Pharma L.P. |
Tissue factor antibodies and uses thereof
|
|
WO2005016970A2
(en)
|
2003-05-01 |
2005-02-24 |
Imclone Systems Incorporated |
Fully human antibodies directed against the human insulin-like growth factor-1 receptor
|
|
CN1972712A
(zh)
|
2003-06-09 |
2007-05-30 |
塞缪尔·瓦克萨尔 |
用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法
|
|
CA2530172A1
(en)
|
2003-06-27 |
2005-02-10 |
Abgenix, Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
|
ATE485307T1
(de)
|
2003-11-07 |
2010-11-15 |
Ablynx Nv |
Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
|
|
CN101337930B
(zh)
*
|
2003-11-11 |
2010-09-08 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
|
TW200526684A
(en)
*
|
2003-11-21 |
2005-08-16 |
Schering Corp |
Anti-IGFR1 antibody therapeutic combinations
|
|
DE10355904A1
(de)
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
|
US7767792B2
(en)
*
|
2004-02-20 |
2010-08-03 |
Ludwig Institute For Cancer Research Ltd. |
Antibodies to EGF receptor epitope peptides
|
|
PT1735348E
(pt)
*
|
2004-03-19 |
2012-07-24 |
Imclone Llc |
Anticorpo anti-receptor do factor de crescimento humano
|
|
US7910593B2
(en)
|
2004-04-09 |
2011-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Water-soluble prodrugs
|
|
KR101699142B1
(ko)
*
|
2004-06-18 |
2017-01-23 |
암브룩스, 인코포레이티드 |
신규 항원-결합 폴리펩티드 및 이의 용도
|
|
US8772269B2
(en)
*
|
2004-09-13 |
2014-07-08 |
Eisai R&D Management Co., Ltd. |
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
|
|
JP4834553B2
(ja)
|
2004-09-17 |
2011-12-14 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
医薬組成物
|
|
WO2006042313A2
(en)
*
|
2004-10-12 |
2006-04-20 |
Imclone Systems Incorporated |
Egfr antagonist in treatment of fluid accumulation
|
|
JP2008519757A
(ja)
*
|
2004-11-12 |
2008-06-12 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
抗ｅｇｆｒ抗体の固形物
|
|
US20090047278A1
(en)
*
|
2005-02-28 |
2009-02-19 |
Eisai R & D Management Co., Ltd. |
Novel Combinational Use of Sulfonamide Compound
|
|
AU2006236637B2
(en)
*
|
2005-04-15 |
2012-09-06 |
Merck Sharp & Dohme Corp. |
Methods and compositions for treating or preventing cancer
|
|
EP1917019A2
(de)
*
|
2005-05-03 |
2008-05-07 |
Biopolymer Engineering, Inc. |
Kombination eines beta-glucans und eines egf-rezeptor-antagonisten zur krebs- und infektionsbehandlung
|
|
CN101287761A
(zh)
|
2005-06-15 |
2008-10-15 |
先灵公司 |
抗-igf1r抗体制剂
|
|
PT2100618E
(pt)
|
2005-06-17 |
2014-04-07 |
Philadelphia Health & Educatio |
Um anticorpo anti-pdgfr-alfa para o tratamento de cancro ósseo metastático
|
|
WO2007015569A1
(ja)
*
|
2005-08-01 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を予測する方法
|
|
JP2007039346A
(ja)
*
|
2005-08-01 |
2007-02-15 |
Yokohama Kokusai Bio Kenkyusho:Kk |
腫瘍特異的抗体と結合したタキソイド誘導体及びその製造方法
|
|
EP1925676A4
(de)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
Testverfahren für die wirkung eines vaskularisierungsinhibitors
|
|
TW200744603A
(en)
|
2005-08-22 |
2007-12-16 |
Chugai Pharmaceutical Co Ltd |
Novel anticancer concomitant drug
|
|
EP1938842A4
(de)
*
|
2005-09-01 |
2013-01-09 |
Eisai R&D Man Co Ltd |
Verfahren zur herstellung einer pharmazeutischen zusammensetzung mit verbesserten zerfallseigenschaften
|
|
US20080199850A1
(en)
|
2005-10-11 |
2008-08-21 |
Merck Patent Gmbh |
Egfr Dependent Modulation of Chemokine Expression and Influence on Therapy and Diagnosis of Tumors and Side Effects Thereof
|
|
JPWO2007052849A1
(ja)
*
|
2005-11-07 |
2009-04-30 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用
|
|
SI1948180T1
(sl)
*
|
2005-11-11 |
2013-06-28 |
Boehringer Ingelheim International Gmbh |
Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
|
|
JP5688877B2
(ja)
|
2005-11-11 |
2015-03-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌疾患の治療用キナゾリン誘導体
|
|
WO2007061127A1
(ja)
*
|
2005-11-22 |
2007-05-31 |
Eisai R & D Management Co., Ltd. |
多発性骨髄腫に対する抗腫瘍剤
|
|
CN101454344A
(zh)
*
|
2005-12-01 |
2009-06-10 |
杜门蒂斯有限公司 |
与白细胞介素-1受体1型结合的非竞争性域抗体形式
|
|
WO2007076923A1
(en)
|
2006-01-04 |
2007-07-12 |
Merck Patent Gmbh |
Combination therapy using anti-egfr and anti-her2 antibodies
|
|
US8323644B2
(en)
*
|
2006-01-17 |
2012-12-04 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
|
JP2009535372A
(ja)
|
2006-05-03 |
2009-10-01 |
バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト |
抗ｅｄｂフィブロネクチンドメイン抗体ｌ１９−ｓｉｐ及び抗−ｅｇｆｒ−抗体の組合せ
|
|
RU2448708C3
(ru)
|
2006-05-18 |
2017-09-28 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое средство против рака щитовидной железы
|
|
EP2044939A1
(de)
*
|
2006-06-29 |
2009-04-08 |
Eisai R&D Management Co., Ltd. |
Therapeutisches mittel gegen leberfibrose
|
|
JP5399900B2
(ja)
|
2006-06-30 |
2014-01-29 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Ｉｇｆｂｐ２インヒビター
|
|
US8865737B2
(en)
|
2006-08-28 |
2014-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
|
CA2676244C
(en)
*
|
2007-01-25 |
2017-01-17 |
Kwok-Kin Wong |
Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
|
|
WO2008093855A1
(ja)
|
2007-01-29 |
2008-08-07 |
Eisai R & D Management Co., Ltd. |
未分化型胃癌治療用組成物
|
|
MX338151B
(es)
*
|
2007-03-01 |
2016-04-05 |
Symphogen As |
Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
|
|
WO2008149147A2
(en)
*
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Polypeptides, antibody variable domains and antagonists
|
|
KR100883430B1
(ko)
*
|
2007-06-13 |
2009-02-12 |
한국생명공학연구원 |
혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
|
|
US20100322939A1
(en)
*
|
2007-06-21 |
2010-12-23 |
Genmab A/S |
Novel methods for treating egfr-associated tumors
|
|
CA2696360C
(en)
*
|
2007-08-14 |
2018-11-20 |
Ludwig Institute For Cancer Research |
Monoclonal antibody targeting the egfr receptor and uses thereof
|
|
CA3128656A1
(en)
|
2007-08-22 |
2009-02-26 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
|
KR101666228B1
(ko)
*
|
2007-09-28 |
2016-10-13 |
인트렉손 코포레이션 |
생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
|
|
WO2009055343A2
(en)
*
|
2007-10-22 |
2009-04-30 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
KR101513326B1
(ko)
|
2007-11-09 |
2015-04-17 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
혈관 신생 저해 물질과 항종양성 백금 착물의 병용
|
|
MX2010008187A
(es)
*
|
2008-01-29 |
2010-08-10 |
Eisai R&D Man Co Ltd |
Uso combinado de inhibidor de angiogenesis y taxano.
|
|
EP2242773B1
(de)
*
|
2008-02-11 |
2017-06-14 |
Cure Tech Ltd. |
Monoklonale antikörper für die tumorbehandlung
|
|
KR20100135780A
(ko)
*
|
2008-03-06 |
2010-12-27 |
제넨테크, 인크. |
Ｃ-ｍｅｔ 및 ｅｇｆｒ 길항제로의 조합 요법
|
|
AR071891A1
(es)
*
|
2008-05-30 |
2010-07-21 |
Imclone Llc |
Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
|
|
CN102137874B
(zh)
|
2008-08-29 |
2015-02-18 |
西福根有限公司 |
抗表皮生长因子受体的重组抗体组合物
|
|
US8583380B2
(en)
|
2008-09-05 |
2013-11-12 |
Aueon, Inc. |
Methods for stratifying and annotating cancer drug treatment options
|
|
EP3543256A1
(de)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modifizierte antikörperzusammensetzungen, verfahren zur herstellung und verwendung davon
|
|
BRPI1011384A2
(pt)
|
2009-02-23 |
2016-03-15 |
Cytomx Therapeutics Inc |
pro-proteinas e seus metodos de uso
|
|
NZ594665A
(en)
|
2009-03-20 |
2013-08-30 |
Genentech Inc |
Bispecific anti-her antibodies
|
|
HUE044629T2
(hu)
|
2009-07-06 |
2019-11-28 |
Boehringer Ingelheim Int |
Eljárás BIBW2992, annak sói, valamint e hatóanyagot tartalmazó szilárd gyógyászati készítmények szárítására
|
|
EP2461870B1
(de)
|
2009-07-22 |
2017-09-06 |
Biothera, Inc. |
Zusammentsetzung enthaltend beta-glucan und ein egf-r-antikörper oder ein egf-r inhibitor zur verwendung in der behandlung von kras-mutierten tumoren
|
|
TH121482A
(th)
|
2009-08-19 |
2013-02-28 |
นางสาวปัณณพัฒน์ เหลืองธาตุทอง |
องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน
|
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
EA020151B1
(ru)
|
2009-10-23 |
2014-09-30 |
Эли Лилли Энд Компани |
Ингибиторы akt и фармацевтические составы, их содержащие
|
|
WO2011107664A1
(en)
|
2010-03-04 |
2011-09-09 |
Hospital District Of Southwest Finland |
Method for selecting patients for treatment with an egfr inhibitor
|
|
EP2371369A1
(de)
|
2010-04-01 |
2011-10-05 |
Institut Gustave Roussy (IGR) |
EGFR-Inhibitor und antivirales Mittel zur gleichzeitigen, getrennten oder aufeinanderfolgenden Verwendung bei der Behandlung und/oder Vorbeugung und/oder Abschwächung von Krebs
|
|
WO2011156617A2
(en)
|
2010-06-09 |
2011-12-15 |
Aveo Pharmaceuticals, Inc. |
Anti-egfr antibodies
|
|
AU2011270165B2
(en)
|
2010-06-25 |
2015-12-24 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
|
US9464136B2
(en)
|
2010-08-20 |
2016-10-11 |
Massachusetts Institute Of Technology |
Antibody-based constructs directed against tyrosine kinase receptors
|
|
CN103228798B
(zh)
|
2010-09-24 |
2015-12-09 |
斯坦福大学托管董事会 |
使用固定的引物直接捕获、扩增及测序靶标dna
|
|
WO2012058418A2
(en)
|
2010-10-27 |
2012-05-03 |
The Research Foundation Of State University Of New York |
Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
|
|
AU2011320318B9
(en)
|
2010-10-29 |
2015-11-19 |
Immunogen, Inc. |
Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
|
|
US8790649B2
(en)
|
2010-10-29 |
2014-07-29 |
Immunogen, Inc. |
EGFR-binding molecules and immunoconjugates thereof
|
|
JP2014503500A
(ja)
|
2010-11-18 |
2014-02-13 |
シンタ ファーマスーティカルズ コーポレーション |
低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
|
|
AU2012239997A1
(en)
|
2011-04-07 |
2013-10-17 |
Amgen Inc. |
Novel EGFR binding proteins
|
|
WO2012144463A1
(ja)
|
2011-04-18 |
2012-10-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療剤
|
|
EP3444363B1
(de)
|
2011-06-03 |
2020-11-25 |
Eisai R&D Management Co., Ltd. |
Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen
|
|
EP3559049B1
(de)
|
2011-10-28 |
2025-06-11 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptidkonstrukte und anwendungen davon
|
|
KR20140105765A
(ko)
|
2011-11-21 |
2014-09-02 |
이뮤노젠 아이엔씨 |
EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법
|
|
JP6324381B2
(ja)
|
2012-07-31 |
2018-05-16 |
クラウン バイオサイエンス インコーポレイテッド（タイカン） |
抗ｅｇｆｒ薬物による処置のための非小細胞肺癌患者を同定するための組織学的マーカー
|
|
EP2882440B1
(de)
|
2012-08-07 |
2019-02-27 |
Novartis AG |
Arzneimittelkombinationen enthaltend einen b-raf-hemmer, einen egfr-hemmer und gegebenenfalls einen pi3k-alpha-hemmer
|
|
KR101645905B1
(ko)
|
2012-10-12 |
2016-08-04 |
스피로즌 살 |
피롤로벤조디아제핀 및 그의 컨주게이트
|
|
RU2015115397A
(ru)
|
2012-12-21 |
2017-01-25 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Аморфная форма производного хинолина и способ его получения
|
|
US20150320861A1
(en)
|
2012-12-21 |
2015-11-12 |
Sykehuset Sørlandet Hf |
Egfr targeted therapy of neurological disorders and pain
|
|
BR112015019348A2
(pt)
|
2013-02-13 |
2017-08-22 |
Lab Francais Du Fractionnement |
Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
|
|
CN105308068A
(zh)
|
2013-02-13 |
2016-02-03 |
法国化学与生物科技实验室 |
高度半乳糖基化的抗TNF-α抗体及其用途
|
|
EP2968585B1
(de)
|
2013-03-13 |
2018-07-18 |
Medimmune Limited |
Pyrrolobenzodiazepine und konjugate davon
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
FI3677591T3
(fi)
|
2013-04-29 |
2023-04-03 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b
|
|
US9914770B2
(en)
*
|
2013-04-30 |
2018-03-13 |
Intas Pharmaceuticals Ltd |
Cloning, expression and purification method for the preparation of ranibizumab
|
|
ES2687968T3
(es)
|
2013-05-14 |
2018-10-30 |
Eisai R&D Management Co., Ltd. |
Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
|
|
IL312865B2
(en)
|
2013-09-11 |
2025-06-01 |
Eagle Biologics Inc |
Liquid protein formulations containing viscosity-lowering agents
|
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
|
BR112016021383A2
(pt)
|
2014-03-24 |
2017-10-03 |
Genentech Inc |
Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
|
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
KR20230043234A
(ko)
|
2014-08-28 |
2023-03-30 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
고순도의 퀴놀린 유도체 및 이를 제조하는 방법
|
|
WO2016037644A1
(en)
|
2014-09-10 |
2016-03-17 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
JP6716577B2
(ja)
|
2014-10-01 |
2020-07-01 |
イーグル・バイオロジクス・インコーポレイテッドＥａｇｌｅ Ｂｉｏｌｏｇｉｃｓ， Ｉｎｃ． |
粘度低下物質を含有する、多糖および核酸の調合薬
|
|
US10385380B2
(en)
|
2014-10-02 |
2019-08-20 |
The Regents Of The University Of California |
Personalized protease assay to measure protease activity in neoplasms
|
|
EP3212787B1
(de)
|
2014-10-28 |
2019-07-10 |
Merck Patent GmbH |
Verfahren zur anzeige von nichtkovalenten fc-domain-haltigen proteinen auf der oberfläche von zellen und verfahren zum screening davon
|
|
EA037749B1
(ru)
|
2014-10-29 |
2021-05-18 |
Тева Фармасьютикалз Острэйлиа Пти Лтд |
ВАРИАНТЫ ИНТЕРФЕРОНА 2b
|
|
CA3204990A1
(en)
|
2014-12-05 |
2016-06-09 |
Xyphos Biosciences Inc. |
Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
|
|
LT3263106T
(lt)
|
2015-02-25 |
2024-01-10 |
Eisai R&D Management Co., Ltd. |
Chinolino darinių kartumo sumažinimo būdas
|
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
MX373231B
(es)
|
2015-06-16 |
2020-05-08 |
Eisai R&D Man Co Ltd |
Agente anticancerigeno.
|
|
FR3038517B1
(fr)
|
2015-07-06 |
2020-02-28 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Utilisation de fragments fc modifies en immunotherapie
|
|
CA2994925C
(en)
|
2015-08-20 |
2023-08-29 |
Eisai R&D Management Co., Ltd. |
Tumor therapeutic agent
|
|
CN105237638A
(zh)
*
|
2015-10-26 |
2016-01-13 |
无锡傲锐东源生物科技有限公司 |
抗egfr蛋白单克隆抗体杂交瘤细胞及其产生的抗egfr单克隆抗体和应用
|
|
RU2018141777A
(ru)
|
2016-04-28 |
2020-05-28 |
Биомюнё Фармасьютикалз |
Биспецифичные антитела, нацеленные на egfr и her2
|
|
MX387795B
(es)
|
2016-06-03 |
2025-03-19 |
Array Biopharma Inc |
Combinaciones farmaceuticas.
|
|
WO2017222556A2
(en)
|
2016-06-24 |
2017-12-28 |
Avidbiotics Corp. |
Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
|
|
JP2019534882A
(ja)
|
2016-10-11 |
2019-12-05 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
免疫介在性療法薬を有する抗体−薬物コンジュゲート
|
|
CN106800599B
(zh)
*
|
2016-12-05 |
2021-03-23 |
中国人民解放军第二军医大学 |
抗人EGFR和Notch多特异性抗体、其制备方法及用途
|
|
US12303505B2
(en)
|
2017-02-08 |
2025-05-20 |
Eisai R&D Management Co., Ltd. |
Tumor-treating pharmaceutical composition
|
|
BR112019023064A2
(pt)
|
2017-05-16 |
2020-06-09 |
Eisai R&D Man Co Ltd |
tratamento de carcinoma hepatocelular
|
|
CA3063324A1
(en)
|
2017-05-16 |
2018-11-22 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
|
JP2020536855A
(ja)
|
2017-09-26 |
2020-12-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
がんを治療するための組成物及び方法
|
|
CA3019207A1
(en)
|
2017-09-28 |
2019-03-28 |
The Governing Council Of The University Of Toronto |
Methods and compositions for inhibiting mutant egfr signaling
|
|
JP2021524449A
(ja)
|
2018-05-23 |
2021-09-13 |
アーデーセー セラピューティクス ソシエテ アノニム |
分子アジュバント
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
WO2020102422A1
(en)
*
|
2018-11-14 |
2020-05-22 |
Arch Oncology, Inc. |
THERAPEUTIC SIRPα ANTIBODIES
|
|
EP3883610A4
(de)
|
2018-11-20 |
2022-11-02 |
Cornell University |
Makrocyclische komplexe von radionukliden und deren verwendung in der radiotherapie von krebs
|
|
CN113677701B
(zh)
|
2019-03-29 |
2025-02-07 |
豪夫迈·罗氏有限公司 |
产生亲合结合多特异性抗体的方法
|
|
WO2020225552A1
(en)
|
2019-05-06 |
2020-11-12 |
Medimmune Limited |
Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
|
|
CA3218661A1
(en)
|
2020-04-04 |
2022-11-17 |
David Campbell |
Compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigens
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
EP4317188A4
(de)
|
2021-03-31 |
2026-01-28 |
Nihon Mediphysics Co Ltd |
Radioaktiver komplex eines anti-egfr-antikörpers und radiopharmazeutikum
|
|
EP4356926A1
(de)
|
2021-06-14 |
2024-04-24 |
Centro de Inmunologia Molecular |
Verwendung von monoklonalen antikörpern gegen den epidermalen wachstumsfaktor-rezeptor zur behandlung von patienten mit akutem hypoxämischem respiratorischem versagen
|
|
KR20240034234A
(ko)
|
2021-07-14 |
2024-03-13 |
2세븐티 바이오, 인코포레이티드 |
항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체
|
|
WO2022078524A2
(en)
|
2021-11-03 |
2022-04-21 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
KR20240154641A
(ko)
|
2022-03-02 |
2024-10-25 |
바이오뮤넥스 파마슈티컬스 |
Her-3, 및 her-2 또는 egfr에 결합하는 이중특이적 항체
|
|
CN119546327A
(zh)
|
2022-04-08 |
2025-02-28 |
再生元制药公司 |
多部分受体和信号传导复合物
|
|
KR20250131777A
(ko)
|
2022-12-07 |
2025-09-03 |
허밍버드 바이오사이언스 피티이. 엘티디. |
암의 치료 및 예방을 위한 조합물
|
|
WO2024126660A1
(en)
|
2022-12-15 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Combination therapy for cancer treatment
|
|
WO2024208881A1
(en)
|
2023-04-06 |
2024-10-10 |
Hummingbird Bioscience Pte. Ltd. |
Treatment and prevention of cancer using her3 antigen-binding molecules
|
|
CN121311246A
(zh)
|
2023-04-14 |
2026-01-09 |
蜂鸟生物科技私人有限公司 |
癌症治疗与预防的组合疗法
|
|
WO2025080592A1
(en)
|
2023-10-09 |
2025-04-17 |
Incyte Corporation |
Combination comprising a kras g12d inhibitor and an egfr inhibitor for use in the treatment of cancer
|
|
EP4545092A1
(de)
|
2023-10-27 |
2025-04-30 |
Technische Universität München |
Rechnerisch entworfene bindemittel für immunzelltherapien
|
|
WO2025238106A1
(en)
|
2024-05-15 |
2025-11-20 |
M6P Therapeutics (Switzerland) GmbH |
Lysosome-targeting degradation fusion design
|
|
WO2025245256A1
(en)
|
2024-05-22 |
2025-11-27 |
Tizona Therapeutics, Inc. |
Combination therapy involving anti-hla-g antibodies and anti- egfr antibodies or anti-pd-1 antibodies
|
|
WO2026019994A1
(en)
|
2024-07-19 |
2026-01-22 |
Genentech, Inc. |
Methods and compositions comprising a shp2 inhibitor and an egfr inhibitor
|